Key points
- The US Food and Drug Administration (FDA) unveiled plans to create an Operation Warp Speed (OWS) programme for genetic medicine, which strives to quicken clinical trials, increase staffing and communication, and ultimately approve relevant drugs at a faster rate.
- We believe that genetic medicine programmes should benefit from the programme.
- We believe the favourable regulatory environment created from Operation Warp Speed could accelerate investment in this industry and increase both drug approvals and revenue potential over time versus current estimates.
The genetic technology revolution has begun, with genetic medicines poised to become the dominant driver of health-care innovation over the next two decades. Regulators around the world are sharing in the mounting enthusiasm for these breakthroughs as they seek to hasten drug approvals. Much like the successful Operation Warp Speed (OWS) programme that expedited Covid-vaccine development, the FDA has unveiled plans to create an OWS programme for genetic medicine. This new iteration strives to quicken clinical trials, increase staffing and communication, and ultimately approve relevant drugs at a faster rate.
Genetic medicines are fast becoming a reality and seek to attack diseases at their source—the DNA or RNA—to provide longer-lasting and more effective outcomes. In some cases, diseases could even be cured. These landscape-changing developments stand in stark contrast to most present-day medicines, which largely treat disease by providing symptom management alone.
Muscular dystrophy as a case study
While genetic therapies can treat a number of ailments, current studies largely target rare diseases. For example, a genetic medicine company focused on muscular dystrophy—a disease with a sizeable unmet medical need and no effective treatments—has developed a gene therapy that adds DNA to a patient’s cells, allowing them to form a protein called micro-dystrophin that helps slow or halt the progression of the disease.
Recently, a panel of experts assembled by the FDA agreed that the drug was safe and effective enough to recommend approval. We expect formal FDA approval to be announced in the next couple of months, ultimately generating significant company revenue. The drug and many others now have clearer and faster paths to market under OWS, giving hope to patients and their families. We think this recent bold stance by the FDA, coupled with robust innovation pipelines, should be a powerful catalyst for value appreciation over the next several years.
A growing investible universe
Recent breakthroughs in genetic medicines are not limited to muscular dystrophy; they are also being developed for other rare diseases such as cardio-myopathies, haemophilia, Huntington’s diseases, amyotrophic lateral sclerosis and many different cancers. We believe these programmes should benefit from OWS. The genetic-medicine investible universe also continues to grow quickly owing to increased public and private investment, with expected revenues rising from $9 billion today to $72 billion by 2030, according to internal Newton estimates.
In our view, the favourable regulatory environment from Operation Warp Speed could quicken investment in this industry and increase both drug approvals and revenue potential over time versus current estimates, creating attractive opportunities for investors.
Authors
Matthew Jenkin
Research analyst, portfolio manager
This is a financial promotion. These opinions should not be construed as investment or other advice and are subject to change. This material is for information purposes only. This material is for professional investors only. Any reference to a specific security, country or sector should not be construed as a recommendation to buy or sell investments in those securities, countries or sectors. Please note that holdings and positioning are subject to change without notice. Compared to more established economies, the value of investments in emerging markets may be subject to greater volatility due to differences in generally accepted accounting principles or from economic, political instability or less developed market practices.
This material is for Australian wholesale clients only and is not intended for distribution to, nor should it be relied upon by, retail clients. This information has not been prepared to take into account the investment objectives, financial objectives or particular needs of any particular person. Before making an investment decision you should carefully consider, with or without the assistance of a financial adviser, whether such an investment strategy is appropriate in light of your particular investment needs, objectives and financial circumstances.
Newton Investment Management Limited is exempt from the requirement to hold an Australian financial services licence in respect of the financial services it provides to wholesale clients in Australia and is authorised and regulated by the Financial Conduct Authority of the UK under UK laws, which differ from Australian laws.
Newton Investment Management Limited (Newton) is authorised and regulated in the UK by the Financial Conduct Authority (FCA), 12 Endeavour Square, London, E20 1JN. Newton is providing financial services to wholesale clients in Australia in reliance on ASIC Corporations (Repeal and Transitional) Instrument 2016/396, a copy of which is on the website of the Australian Securities and Investments Commission, www.asic.gov.au. The instrument exempts entities that are authorised and regulated in the UK by the FCA, such as Newton, from the need to hold an Australian financial services license under the Corporations Act 2001 for certain financial services provided to Australian wholesale clients on certain conditions. Financial services provided by Newton are regulated by the FCA under the laws and regulatory requirements of the United Kingdom, which are different to the laws applying in Australia.
